Aging, Plasminogen Activator Inhibitor 1, Brain Cell Senescence, and Alzheimer’s Disease

The etiology for late-onset Alzheimer’s disease (LOAD), which accounts for >95% of Alzheimer’s disease (AD) cases, is unknown. Emerging evidence suggests that cellular senescence contributes importantly to AD pathophysiology, although the mechanisms underlying brain cell senescence and by which senescent cells promote neuro-pathophysiology remain unclear. In this study we show for the first time that the expression of plasminogen activator inhibitor 1 (PAI-1), a serine protease inhibitor, is increased, in correlation with the increased expression of cell cycle repressors p53 and p21, in the hippocampus/cortex of senescence accelerated mouse prone 8 (SAMP8) mice and LOAD patients. Double immunostaining results show that astrocytes in the brain of LOAD patients and SAMP8 mice express higher levels of senescent markers and PAI-1, compared to astrocytes in the corresponding controls. In vitro studies further show that overexpression of PAI-1 alone, intracellularly or extracellularly, induced senescence, whereas inhibition or silencing PAI-1 attenuated H2O2-induced senescence, in primary mouse and human astrocytes. Treatment with the conditional medium (CM) from senescent astrocytes induced neuron apoptosis. Importantly, the PAI-1 deficient CM from senescent astrocytes that overexpress a secretion deficient PAI-1 (sdPAI-1) has significantly reduced effect on neurons, compared to the PAI-1 containing CM from senescent astrocytes overexpressing wild type PAI-1 (wtPAI-1), although sdPAI-1 and wtPAI-1 induce similar degree of astrocyte senescence. Together, our results suggest that increased PAI-1, intracellularly or extracellularly, may contribute to brain cell senescence in LOAD and that senescent astrocytes can induce neuron apoptosis through secreting pathologically active molecules, including PAI-1.

[1]  T. Jiang,et al.  ACE2 activator diminazene aceturate ameliorates Alzheimer's disease-like neuropathology and rescues cognitive impairment in SAMP8 mice , 2020, Aging.

[2]  Jie Liu,et al.  SAMP8 Mice as a Model of Age-Related Cognition Decline with Underlying Mechanisms in Alzheimer's Disease. , 2020, Journal of Alzheimer's disease : JAD.

[3]  Takayoshi Suzuki,et al.  Early sirtuin 2 inhibition prevents age-related cognitive decline in a senescence-accelerated mouse model , 2019, Neuropsychopharmacology.

[4]  P. Caramelli,et al.  Hemostatic Abnormalities in Dementia: A Systematic Review and Meta-Analysis , 2019, Seminars in Thrombosis and Hemostasis.

[5]  D. Holtzman,et al.  Senescent glia spell trouble in Alzheimer’s disease , 2019, Nature Neuroscience.

[6]  M. Gorospe,et al.  Senolytic therapy alleviates Aβ-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer’s disease model , 2019, Nature Neuroscience.

[7]  J. Hort,et al.  Amyloid beta soluble forms and plasminogen activation system in Alzheimer’s disease: Consequences on extracellular maturation of brain‐derived neurotrophic factor and therapeutic implications , 2018, CNS neuroscience & therapeutics.

[8]  R. Hortigüela,et al.  Noggin rescues age-related stem cell loss in the brain of senescent mice with neurodegenerative pathology , 2018, Proceedings of the National Academy of Sciences.

[9]  N. Musi,et al.  Tau protein aggregation is associated with cellular senescence in the brain , 2018, Aging cell.

[10]  D. Baker,et al.  Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline , 2018, Nature.

[11]  D. Allison,et al.  Senolytics Improve Physical Function and Increase Lifespan in Old Age , 2018, Nature Medicine.

[12]  Ronald C Petersen,et al.  Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives. , 2018, The Journal of clinical investigation.

[13]  M. Gorospe,et al.  Stress granules counteract senescence by sequestration of PAI‐1 , 2018, EMBO reports.

[14]  T. Miyata,et al.  TGF-β-induced intracellular PAI-1 is responsible for retaining hematopoietic stem cells in the niche. , 2017, Blood.

[15]  Sanjiv J. Shah,et al.  A null mutation in SERPINE1 protects against biological aging in humans , 2017, Science Advances.

[16]  P. Flevaris,et al.  PAI-1 is a critical regulator of FGF23 homeostasis , 2017, Science Advances.

[17]  Gang Liu,et al.  Serpine 1 induces alveolar type II cell senescence through activating p53‐p21‐Rb pathway in fibrotic lung disease , 2017, Aging cell.

[18]  T. Rantamäki,et al.  Modulation of BDNF cleavage by plasminogen-activator inhibitor-1 contributes to Alzheimer's neuropathology and cognitive deficits. , 2017, Biochimica et biophysica acta. Molecular basis of disease.

[19]  A. Oberg,et al.  Cellular senescence mediates fibrotic pulmonary disease , 2017, Nature Communications.

[20]  Zhaoxu Zhang,et al.  Fuzhisan Ameliorates the Memory Deficits in Aged SAMP8 Mice via Decreasing Aβ Production and Tau Hyperphosphorylation of the Hippocampus , 2016, Neurochemical Research.

[21]  A. Pezeshki,et al.  Naturally occurring p16Ink4a-positive cells shorten healthy lifespan , 2016, Nature.

[22]  D. Baker,et al.  Cellular senescence in aging and age-related disease: from mechanisms to therapy , 2015, Nature Medicine.

[23]  Hye-Ja Lee,et al.  Plasminogen activator inhibitor-1 as an early potential diagnostic marker for Alzheimer's disease , 2014, Experimental Gerontology.

[24]  Koji Yamamoto,et al.  Plasminogen Activator Inhibitor-1 in Aging , 2014, Seminars in Thrombosis & Hemostasis.

[25]  De-Pei Liu,et al.  SIRT1-mediated epigenetic downregulation of plasminogen activator inhibitor-1 prevents vascular endothelial replicative senescence , 2014, Aging cell.

[26]  G. Mutlu,et al.  PAI-1–regulated extracellular proteolysis governs senescence and survival in Klotho mice , 2014, Proceedings of the National Academy of Sciences.

[27]  W. Banks,et al.  SAMP8 mice have altered hippocampal gene expression in long term potentiation, phosphatidylinositol signaling, and endocytosis pathways , 2014, Neurobiology of Aging.

[28]  Xiaorui Cheng,et al.  The behavioral, pathological and therapeutic features of the senescence-accelerated mouse prone 8 strain as an Alzheimer's disease animal model , 2014, Ageing Research Reviews.

[29]  S. Weintraub,et al.  Plasminogen activator inhibitor 1 - insulin-like growth factor binding protein 3 cascade regulates stress-induced senescence , 2012, Proceedings of the National Academy of Sciences.

[30]  J. Morley,et al.  The senescence accelerated mouse (SAMP8) as a model for oxidative stress and Alzheimer's disease. , 2012, Biochimica et biophysica acta.

[31]  J. Jordán,et al.  Sildenafil ameliorates cognitive deficits and tau pathology in a senescence-accelerated mouse model , 2012, Neurobiology of Aging.

[32]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[33]  A. Budovsky,et al.  Molecular links between cellular senescence, longevity and age-related diseases – a systems biology perspective , 2011, Aging.

[34]  N. LeBrasseur,et al.  Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders , 2011, Nature.

[35]  T. Groen,et al.  Knockout of plasminogen activator inhibitor 1 gene reduces amyloid beta peptide burden in a mouse model of Alzheimer's disease , 2011, Neurobiology of Aging.

[36]  M. Alessi,et al.  Plasminogen activator inhibitor 1 is an intracellular inhibitor of furin proprotein convertase , 2011, Journal of Cell Science.

[37]  C. Cierniewski,et al.  Plasminogen Activator Inhibitor Type 1 Interacts with α3 Subunit of Proteasome and Modulates Its Activity* , 2010, The Journal of Biological Chemistry.

[38]  T. Comery,et al.  Enhanced clearance of Aβ in brain by sustaining the plasmin proteolysis cascade , 2008, Proceedings of the National Academy of Sciences.

[39]  R. Bernards,et al.  Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence , 2006, Nature Cell Biology.

[40]  Koji Yamamoto,et al.  Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly. , 2005, Cardiovascular research.

[41]  Y. Nomura,et al.  Senescence-accelerated mouse (SAM) as an animal model of senile dementia: pharmacological, neurochemical and molecular biological approach. , 1998, Japanese journal of pharmacology.

[42]  J. Morley,et al.  Age-related changes in learning, memory, and lipofuscin as a function of the percentage of SAMP8 genes , 1995, Physiology & Behavior.

[43]  M. Hosokawa,et al.  Senescence‐Accelerated Mouse (SAM): A Novel Murine Model of Accelerated Senescence , 1991, Journal of the American Geriatrics Society.

[44]  Ichiro Akiguchi,et al.  Age-related deterioration of ability of acquisition in memory and learning in senescence accelerated mouse: SAM-P/8 as an animal model of disturbances in recent memory , 1988, Brain Research.

[45]  M. Alessi,et al.  Increase in Plasma Concentrationof Plasminogen Activator Inhibitor, Fibrinogen, von Willebrand Factor, Factor VIII: Cand in Erythrocyte Sedimentation Rate with Age , 1986, Thrombosis and Haemostasis.

[46]  Gang Liu,et al.  PAI-1 Regulation of TGF-b1–induced Alveolar Type II Cell Senescence, SASP Secretion, and SASP-mediated Activation of Alveolar Macrophages , 2020 .

[47]  J. Morley,et al.  Metformin Improves Learning and Memory in the SAMP8 Mouse Model of Alzheimer's Disease. , 2019, Journal of Alzheimer's disease : JAD.

[48]  J. del Valle,et al.  Characterization of amyloid-β granules in the hippocampus of SAMP8 mice. , 2011, Journal of Alzheimer's Disease.

[49]  Charles Duyckaerts,et al.  National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach , 2011, Acta Neuropathologica.

[50]  J. Baker,et al.  Expression and Functional Significance of SOCS-1 and SOCS-3 in Astrocytes , 2008 .